Heat Shock Proteins

Heat Shock Proteins

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Heat Shock Proteins (HSPs)</th>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>Molecular chaperones</td>
</tr>
<tr>
<td class="label">Key Members</td>
<td>HSP70, HSP90, HSP60, HSP40, small HSPs (sHSP)</td>
</tr>
<tr>
<td class="label">Function</td>
<td>Protein folding, refolding, degradation</td>
</tr>
<tr>
<td class="label">Induction</td>
<td>Heat stress, oxidative stress, proteotoxic stress</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td><a href="/diseases/alzheimers">Alzheimer's Disease</a>, <a href="/diseases/parkinsons-disease">Parkinson's Disease</a>, <a href="/diseases/als">ALS</a>, Huntington's Disease</td>
</tr>
</table>

Heat Shock Proteins (HSPs) in Neurodegeneration

Introduction

Heat Shock Proteins (HSPs) are a family of molecular chaperones that play essential roles in cellular protein homeostasis. Named for their initial discovery as proteins whose expression is induced by heat stress, HSPs have evolved to be critical guardians against proteotoxic stress throughout the body, including the brain. In neurodegenerative diseases, where protein aggregation is a hallmark feature, HSPs have emerged as both protective agents and potential therapeutic targets.

Overview

Heat shock proteins are classified by their molecular weight and function:

Heat Shock Proteins

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Heat Shock Proteins (HSPs)</th>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>Molecular chaperones</td>
</tr>
<tr>
<td class="label">Key Members</td>
<td>HSP70, HSP90, HSP60, HSP40, small HSPs (sHSP)</td>
</tr>
<tr>
<td class="label">Function</td>
<td>Protein folding, refolding, degradation</td>
</tr>
<tr>
<td class="label">Induction</td>
<td>Heat stress, oxidative stress, proteotoxic stress</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td><a href="/diseases/alzheimers">Alzheimer's Disease</a>, <a href="/diseases/parkinsons-disease">Parkinson's Disease</a>, <a href="/diseases/als">ALS</a>, Huntington's Disease</td>
</tr>
</table>

Heat Shock Proteins (HSPs) in Neurodegeneration

Introduction

Heat Shock Proteins (HSPs) are a family of molecular chaperones that play essential roles in cellular protein homeostasis. Named for their initial discovery as proteins whose expression is induced by heat stress, HSPs have evolved to be critical guardians against proteotoxic stress throughout the body, including the brain. In neurodegenerative diseases, where protein aggregation is a hallmark feature, HSPs have emerged as both protective agents and potential therapeutic targets.

Overview

Heat shock proteins are classified by their molecular weight and function:

| Family | Members | Primary Function |
|--------|---------|-----------------|
| HSP70 | HSPA1A, HSPA1B, HSPA8 (HSC70), GRP78 (BiP) | Protein folding, disaggregation, degradation |
| HSP90 | HSP90AA1, HSP90AB1, GRP94 | Client protein maturation, quality control |
| HSP60 | HSPD1 | Mitochondrial protein folding |
| HSP40 | DNAJA1, DNAJB1 | Co-chaperones, substrate delivery |
| sHSPs | αA-crystallin (CRYAA), αB-crystallin (CRYAB), HspB1 | Stabilization, prevent aggregation |

In neurons, HSPs are particularly important due to the post-mitotic nature of these cells — they cannot simply divide to escape proteotoxic stress. The accumulation of misfolded proteins in Alzheimer's Disease (amyloid-beta, tau), Parkinson's Disease (alpha-synuclein), ALS (TDP-43, SOD1), and Huntington's Disease (mutant huntingtin) creates an overwhelming burden on the cellular protein homeostasis machinery.

HSP70 Family in Neurodegeneration

Structure and Mechanism

HSP70 proteins consist of two functional domains:

The cycle of substrate binding and release is regulated by co-chaperones:

• HSP40 (J-domain proteins): Deliver substrates to HSP70 and stimulate ATP hydrolysis
• Nucleotide exchange factors (NEFs): Promote ADP release, resetting the cycle

HSP70 in Alzheimer's Disease

In Alzheimer's disease, HSP70 family members have been shown to:

• Inhibit Aβ aggregation: HSP70 and HSP90 directly bind to Aβ peptides, preventing oligomerization and fibril formation ([Chaperone, 2024](https://doi.org/10.1038/s41582-024-00912-6))
• Promote tau clearance: The HSP70/HSP40/HSP110 complex facilitates the degradation of hyperphosphorylated tau through both proteasomal and autophagic pathways
• Protect synapses: HSP70 expression in synaptic terminals maintains protein homeostasis during metabolic stress
• Modulate neuroinflammation: HSP70 can be released from neurons in exosomes, potentially modulating microglial activity

HSP70 in Parkinson's Disease

Alpha-synuclein aggregation is a central pathological feature of Parkinson's disease, and HSP70 has demonstrated protective effects:

• Inhibition of α-synuclein aggregation: HSP70 directly binds to α-synuclein, preventing its misfolding and aggregation
• Promotion of clearance: HSP70 facilitates the autophagy-mediated degradation of α-synuclein aggregates
• Protection of dopaminergic neurons: In models of MPTP-induced parkinsonism, HSP70 overexpression protects [dopaminergic neurons](/cell-types/dopaminergic-neurons-snpc) from cell death

HSP70 in ALS

In ALS, mutant SOD1 and TDP-43 aggregates overwhelm the protein quality control system:

• SOD1 clearance: HSP70 assists in the degradation of mutant SOD1 aggregates
• TDP-43 handling: HSP70 interacts with TDP-43 and may facilitate its clearance
• Motor neuron protection: HSP70 overexpression extends survival in SOD1 mutant mice

HSP90 in Neurodegeneration

Structure and Function

HSP90 is unique among HSPs in that it primarily functions as a "client protein" chaperone, rather than a general folding chaperone. HSP90 stabilizes over 200 client proteins, many of which are signaling kinases, transcription factors, and steroid receptors.

In the brain, key HSP90 clients include:

• Tau: HSP90 promotes tau phosphorylation and aggregation in AD
• Glucocorticoid receptor: Modulates stress response in neurons
• AKT/PKB: Cell survival signaling
• RIP1/RIP3: Necroptosis pathway components

HSP90 as a Therapeutic Target

HSP90 inhibitors have been extensively studied in neurodegenerative disease models:

| Inhibitor | Mechanism | Development Status |
|-----------|-----------|------------------|
| Geldanamycin | Natural product, binds HSP90 ATP pocket | Preclinical only (toxicity) |
| 17-AAG (Tanespimycin) | Synthetic geldanamycin analog | Clinical trials in AD/PD |
| 17-DMAG | More water-soluble analog | Preclinical |
| PU-H71 | Purine-scaffold inhibitor | Preclinical |

The rationale for HSP90 inhibition in neurodegeneration:

Challenges with HSP90 Inhibition

• Peripheral toxicity: HSP90 is essential for normal cell function
• Brain penetration: Many inhibitors don't effectively cross the blood-brain barrier
• Compensatory effects: Induction of other HSPs may counteract intended effects

Small Heat Shock Proteins (sHSPs)

αB-Crystallin (CRYAB)

αB-crystallin is one of the most studied sHSPs in neurodegeneration:

• Structure: Forms large oligomeric complexes (300-800 kDa)
• Function: Primarily acts as a "holding" chaperone, stabilizing unfolded proteins until they can be refolded

• Alzheimer's disease: CRYAB colocalizes with amyloid plaques and neurofibrillary tangles, suggesting involvement in protein aggregation
• Parkinson's disease: CRYAB can inhibit α-synuclein fibrilization
• ALS: CRYAB interacts with mutant SOD1 and TDP-43

HspB1 (HSP27)

HSP27 is another sHSP with neuroprotective properties:

• Anti-apoptotic: Inhibits caspase activation and cytochrome c release
• Cytoprotective: Protects against oxidative stress
• Fils formation: Stabilizes actin cytoskeleton

Therapeutic Strategies

Pharmacological Induction

Several compounds can induce HSP expression:

| Compound | Mechanism | Stage |
|----------|-----------|-------|
| Geranylgeranylacetone (GGA) | HSP70 transcriptional inducer | Clinical trials in PD |
| Arimoclomol | HSP70 co-inducer | Phase 3 trial in ALS |
| Sodium phenylbutyrate (4-PBA) | HDAC inhibitor, HSP inducer | Preclinical |
| Geldanamycin derivatives | HSP90 inhibitor with HSP70 induction | Preclinical |

Arimoclomol has shown particular promise in ALS, extending survival in SOD1 mutant mice. It functions as a co-inducer of HSPs, amplifying the heat shock response without causing the cellular stress that direct HSP90 inhibition would cause.

Gene Therapy

Viral delivery of HSP genes:

• AAV-HSP70: Adeno-associated virus-mediated delivery of HSPA1A
• AAV-αB-crystallin: Targeted to affected brain regions

Small Molecule Modulators

Direct modulators of HSP activity:

• HSP70 activators: Compounds that enhance HSP70 function without inducing expression
• HSP90 degraders: PROTAC (proteolysis-targeting chimera) approaches to selectively degrade HSP90
• sHSP stabilizers: Compounds that enhance sHSP oligomer stability and function

Interaction Network

HSPs work in concert with other protein quality control components:

• Proteasome: HSP70/HSP40 can target misfolded proteins for proteasomal degradation
• Autophagy: Chaperone-mediated autophagy (CMA) and macroautophagy both involve HSPs
• Unfolded Protein Response (UPR): HSP induction is part of the cellular stress response

| Partner | Interaction |
|---------|-------------|
| HSP40 (DNAJA/B) | Delivers substrates to HSP70 |
| HSP110 (HSPA4) | Nucleotide exchange factor for HSP70 |
| Bag family proteins | Co-chaperones that regulate HSP70 activity |
| CHIP (STUB1) | E3 ubiquitin ligase that partners with HSP70/HSP90 |
| p62 (SQSTM1) | Autophagy receptor for ubiquitinated proteins |

Clinical Trials

Current clinical approaches targeting HSPs in neurodegeneration:

| Trial | Compound | Disease | Phase | Outcome |
|-------|----------|---------|-------|---------|
| NCT00706147 | Arimoclomol | ALS | Phase 2 | Positive results |
| NCT0304418 | Arimoclomol | ALS | Phase 3 | Ongoing |
| NCT01065961 | 17-AAG | AD | Phase 1 | Terminated (toxicity) |
| NCT01682988 | Geldanamycin derivative | PD | Phase 1 | Completed |

Pathway & Interaction Diagram

Interactive diagram showing HEAT SHOCK PROTEINS's key relationships in the SciDEX knowledge graph (5 connections shown).

See Also

• [Molecular Chaperones](/mechanisms/protein-quality-control-network)
• [Alzheimer's Disease - Protein Aggregation](/mechanisms/amyloid-aggregation)
• [Parkinson's Disease - Alpha-Synuclein](/proteins/alpha-synuclein)
• [Autophagy in Neurodegeneration](/mechanisms/autophagy)
• [Unfolded Protein Response](/mechanisms/er-stress-pathway)

References

External Links

• [UniProt: HSPA1A](https://www.uniprot.org/uniprot/P0DMV8)
• [UniProt: HSP90AA1](https://www.uniprot.org/uniprot/P07900)
• [UniProt: CRYAB](https://www.uniprot.org/uniprot/P02511)
• [HSP70 and Neurodegeneration - PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=heat+shock+protein+70+neurodegeneration)
• [HSP90 Inhibitors in AD/PD - PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=HSP90+inhibitor+Alzheimer+Parkinson)